8. Technical Glas et al. (2006) Conversion to diagnostic http://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-7-278 October 30, Converting a breast test study. 162 patients 2006. cancer microarray used to compare data to signature into a original study (no. 6 diagnostic above). Demonstrated test. BMC Genomics; reproducibility and 7:278. robustness of microarray results suggesting its utility as a tool to predict disease outcome. 9 Technical Sapino et al. (2014) Validation of http://jmd.amjpathol.org/article/S1525-1578(13)00253-5/abstract March, 2014. comparison MammaPrint Molecular MammaPrint in FFPE of methods. Diagnostics on specimen. 211 patients. Formalin-Fixed, Comparison made Paraffin-Embedded between FFPE and Tissue. J Mol Diagn; tissue equivalents. 16(2): 190-197. Demonstrated FFPE results substantially equivalent to fresh tissue results.
8. Technical Glas et al. (2006) Converting a breast cancer microarray signature into a diagnostic test. BMC Genomics; 7:278. Conversion to diagnostic test study. 162 patients used to compare data to original study (no. 6 above). Demonstrated reproducibility and robustness of microarray results suggesting its utility as a tool to predict disease outcome. http://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-7-278 October 30, 2006. 9 Technical comparison of methods. Sapino et al. (2014) MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue. J Mol Diagn; 16(2): 190-197. Validation of MammaPrint in FFPE specimen. 211 patients. Comparison made between FFPE and tissue equivalents. Demonstrated FFPE results substantially equivalent to fresh tissue results. http://jmd.amjpathol.org/article/S1525-1578(13)00253-5/abstract March, 2014.
MSAC%20Application%201376.1_MammaPrint%20redacted.docx